Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa

NCT ID: NCT04864496

Last Updated: 2021-04-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-17
• Study Completion Date: 2022-12-20

Brief Summary

Retinitis pigmentosa (RP) is an inherited retinal disease with great heterogeneity. RP comprises a large group of genetic disorders causing progressive loss of vision. Despite many suggested treatments, there is actually no effective therapy for most types of RP at present. Mutations that cause RP initially lead to rod cell death. After rod photoreceptors' death, cone photoreceptors also gradually die. There are several hypotheses as to why mutation-induced rod photoreceptor cell death invariably leads to gradual dysfunction and death of cone photoreceptors resulting in severe visual acuity loss and blindness. Rods constitute 95 percent of cells in the outer retina. As they degenerate, oxygen consumption is reduced and the level of tissue oxygen markedly increases. After rods degeneration, several markers of oxidative damage appear in cones. This oxidative stress over time may lead to cone dysfunction and death. Antioxidants reduce markers of oxidative damage and promote cone function and survival. In RP, cone death occurs as a result of the death of rods, rather than as the result of the pathogenic mutations and therefore treatment with antioxidants may have the potential to be applied to all patients with RP irrespective of the disease-causing mutation.

N-acetylcysteine is a derivative of L cysteine that plays a role in the biosynthesis of glutathione and neutralizes reactive oxygen species. It also has a direct antioxidant activity via its reactive sulfhydryl agent. Its systemic use shows an acceptable safety profile. It has been shown that the use of systemic N-acetylcysteine provides significant intraocular concentration and antioxidant activity that may lead to the promotion of cone function and survival.

In a recent phase 1 randomized clinical trial (RCT), it was revealed that oral N-acetylcysteine (NAC) was safe and well-tolerated in patients with moderately advanced RP and might improve sub-optimally functioning macular cones. The authors concluded that a randomized, placebo-controlled trial is needed to determine if oral NAC can provide long-term stabilization and/or improvement in visual function in patients with RP. In this phase 2 RCT, eligible patients with the diagnosis of moderately advanced RP are randomly divided into two groups; treatment group (N-acetylcysteine tablets) and controls (placebo). Each group will be treated for 6 months. In this study, we will investigate if the use of oral N- acetylcysteine as a potent antioxidant agent can slow down or reverse the disease process in RP patients with prior moderate loss of vision. It may potentially demonstrate a treatment modality regardless of the genetic type of RP. The primary outcome measure will be the stability or improvement of the best-corrected visual acuity (BCVA). The secondary outcome measures will be changes in color vision, electroretinogram, visual field, structural OCT indices after 6 months. The same parameters will be re-evaluated 3 months after discontinuation of treatment at month 9.

Conditions

Retinitis Pigmentosa

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Prescribe N-acetylcysteine tablets

Group Type: ACTIVE_COMPARATOR

Prescribe N-acetylcysteine tablets

Intervention Type: DRUG

N-acetylcysteine tablets ,1200 mg two times daily

Prescribe placebo tablets

Group Type: PLACEBO_COMPARATOR

Prescribe placebo tablets

Intervention Type: DRUG

manufactured by Daroo Salamat Pharmed, two times daily

Interventions

Prescribe N-acetylcysteine tablets

N-acetylcysteine tablets ,1200 mg two times daily

Intervention Type: DRUG

Prescribe placebo tablets

manufactured by Daroo Salamat Pharmed, two times daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• RP patients with the best-corrected visual acuity (BCVA) between 20/30 and 20/120.

Exclusion Criteria

• Patients with other types of retinal dystrophy
• Systemic or syndromic RP
• RP patients with cystoid macular edema (CME) and the presence of cystoid changes in the foveal area
• RP patients with other concomitant ocular diseases
• RP patients with a history of any ocular surgery or intravitreal injection within 6 months before the study enrollment
• RP patients who have received any supplemental drugs during the past three months before the study enrollment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shahid Beheshti University of Medical Sciences

OTHER

Sponsor Role: lead

Responsible Party

Zahra Rabbani Khah

Head of ophthalmic research center

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Ophthalmic Research Center

Tehran, , Iran

Countries

Iran

Other Identifiers

1400

Identifier Type: -

Identifier Source: org_study_id